Business Description
Palisade Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US6963892046
Description
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 61.62 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 78 | |||||
3-Year EPS without NRI Growth Rate | 78.8 | |||||
3-Year FCF Growth Rate | 72.6 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.44 | |||||
9-Day RSI | 45.35 | |||||
14-Day RSI | 43.34 | |||||
6-1 Month Momentum % | -42.39 | |||||
12-1 Month Momentum % | -83.04 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.87 | |||||
Quick Ratio | 4.87 | |||||
Cash Ratio | 4.57 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -298.9 | |||||
Shareholder Yield % | -167.21 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -4314.8 | |||||
ROE % | -103.74 | |||||
ROA % | -87.21 | |||||
ROIC % | -922.51 | |||||
ROC (Joel Greenblatt) % | -5796.47 | |||||
ROCE % | -102.1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.19 | |||||
PB Ratio | 0.38 | |||||
Price-to-Tangible-Book | 0.38 | |||||
EV-to-EBIT | 0.51 | |||||
EV-to-EBITDA | 0.51 | |||||
EV-to-Revenue | -27.55 | |||||
EV-to-Forward-Revenue | 0.76 | |||||
EV-to-FCF | 0.64 | |||||
Price-to-Net-Current-Asset-Value | 0.41 | |||||
Price-to-Net-Cash | 0.44 | |||||
Earnings Yield (Greenblatt) % | 196.08 | |||||
FCF Yield % | -256.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PALI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Palisade Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.25 | ||
EPS (TTM) ($) | -23.64 | ||
Beta | 1.26 | ||
Volatility % | 87.17 | ||
14-Day RSI | 43.34 | ||
14-Day ATR ($) | 0.345717 | ||
20-Day SMA ($) | 4.568 | ||
12-1 Month Momentum % | -83.04 | ||
52-Week Range ($) | 3.82 - 36.599999 | ||
Shares Outstanding (Mil) | 0.94 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Palisade Bio Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Palisade Bio Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Palisade Bio Inc Frequently Asked Questions
What is Palisade Bio Inc(PALI)'s stock price today?
The current price of PALI is $4.49. The 52 week high of PALI is $36.60 and 52 week low is $3.82.
When is next earnings date of Palisade Bio Inc(PALI)?
The next earnings date of Palisade Bio Inc(PALI) is 2024-08-15 Est..
Does Palisade Bio Inc(PALI) pay dividends? If so, how much?
Palisade Bio Inc(PALI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |